Publications by authors named "M Al-Rabia"

Background: This six-year retrospective study provides an in-depth analysis of the epidemiological and clinical patterns associated with () infections, focusing on age distribution, antibiotic resistance profiles, and specimen types.

Aim: The research examines the incidence and characteristics of non-Multi-Drug Resistant (non-MDR) and Multi-Drug Resistant (MDR) strains by reviewing patient records from January 2016 to December 2022.

Methods: Through a statistical analysis, the study highlights the incidence rates across diverse age groups and explores the impact of antibiotic treatment regimens on infection outcomes.

View Article and Find Full Text PDF

Objective: Currently, there is a limited amount of published data on the incidence of bloodstream infections (BSI) caused by both methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) in most parts of the Arabian Peninsula. Thus, it is extremely important to have information concerning the distribution and prevalence of MRSA and MSSA to better handle and manage future epidemics.  This study aimed to investigate the correlation between MRSA and/or MSSA with BSI at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia.

View Article and Find Full Text PDF

The clinical use of 5-fluorouracil (5-FU) in cancer patients has been associated with nephrotoxicity, which is greatly curbing its therapeutic application. The pathogenesis of 5-FU-induced nephrotoxicity is complex; however, oxidative stress-mediated inflammation is considered a central pathogenic factor. Urolithin B (UB), a product of ellagitannins, has recently been assigned diverse pharmacological activities due to its potent antioxidant and anti-inflammatory properties.

View Article and Find Full Text PDF
Article Synopsis
  • Resistance to antibiotics is a serious health issue that needs quick solutions, and using anti-virulence agents like cilostazol may be a good strategy.*
  • Cilostazol, a drug already used for other health problems, was tested to see if it could help stop harmful bacteria, like Pseudomonas aeruginosa, from causing infections.*
  • The study found that cilostazol could reduce the bacteria's ability to form harmful groups and damage organs, and it worked well together with antibiotics, which could help fight infections better without leading to more resistance.*
View Article and Find Full Text PDF